<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159570</url>
  </required_header>
  <id_info>
    <org_study_id>00550</org_study_id>
    <nct_id>NCT05159570</nct_id>
  </id_info>
  <brief_title>Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects. (KETO-HFpEF-Metabolic)</brief_title>
  <official_title>Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Metabolic Effects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes&#xD;
      (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial effects in patients&#xD;
      with hearth failure with reduced ejection fraction. However, this have never been&#xD;
      investigated in patients with heart failure with preserved ejection fraction (HFpEF).&#xD;
&#xD;
      In this study we would like to investigate the effect of 14 days modulation of circulating&#xD;
      ketone body levels on whole body and skeletal metabolism in patients with HFpEF and T2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2022</start_date>
  <completion_date type="Anticipated">May 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in lipolysis rate</measure>
    <time_frame>After 14 days treatment</time_frame>
    <description>Measured as differences in palmitate flux</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose kinetic</measure>
    <time_frame>After 14 days treatment</time_frame>
    <description>Measured by glucose tracer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in signaling in muscle and adipose tissue</measure>
    <time_frame>After 14 days treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Ketonemia</condition>
  <arm_group>
    <arm_group_label>Ketone ester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone ester</intervention_name>
    <description>Commercially available ketone supplement</description>
    <arm_group_label>Ketone ester</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo drink</intervention_name>
    <description>Isocaloric placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (i) Type 2 diabetes, (ii) LVEF &gt; 40 %, (iii) a clinical diagnosis of HFpEF and/or left&#xD;
        ventricular hypertrophy (posterior wall thickness &gt; 12 mm) and/or previous myocardial&#xD;
        infarction, (iiii) age ≥ 18 years old, and (iv) one of the following criteria (a-d) should&#xD;
        be fulfilled:&#xD;
&#xD;
        Echocardiographic signs of diastolic dysfunction E/e' &gt; 8 Septal e ́&lt; 7 cm/s and/or lateral&#xD;
        e ́ &lt; 10 cm/s Left atrium volume index ≥34 mL/m2 and/or left atrial diameter &gt; 4 cm&#xD;
        NT-proBNP &gt; 125 pg/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Insulin treatment, inability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nigopan Gopalasingam, MD</last_name>
    <phone>+4531535950</phone>
    <email>niggop@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik Wiggers, Professor</last_name>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Ketosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

